The Latest Cardiac and Vascular News
– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the application was filed for […]
NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol and can be combined with other treatments to help lower cholesterol even further1 Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in […]
NILEMDO® (bempedoic acid) is a new, first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering treatment that significantly reduces LDL-C on top of statins and other lipid-lowering therapies1 Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in […]
